Summary
Abbott Laboratories (ABT) reported its second quarter 2020 results on July 29, 2020, reflecting the initial impacts of the COVID-19 pandemic across its diverse business segments. Total net sales for the quarter were $7.33 billion, a decrease of 8.2% compared to the prior year, with a 5.4% decrease excluding foreign exchange impacts. The Medical Devices segment saw a significant 21.2% decline in sales, primarily due to reduced procedure volumes resulting from the pandemic. Conversely, the Diagnostic Products segment experienced a 4.7% increase in sales, boosted by the launch and sales of new COVID-19 testing solutions. For the six months ended June 30, 2020, total net sales were $15.05 billion, down 3.0% from the prior year (down 0.7% excluding foreign exchange). Earnings from continuing operations were $1.08 billion for the six months, a decrease from $1.68 billion in the prior year, reflecting the pandemic's effects. The company highlighted its rapid development and launch of six COVID-19 diagnostic tests, contributing $652 million in sales during the first six months of 2020. Despite the challenges, Abbott demonstrated resilience with growth in its Nutritional and Molecular Diagnostics businesses, and significant upside in its Diabetes Care products, notably the FreeStyle Libre system.
Financial Highlights
51 data points| Revenue | $7.33B |
| Cost of Revenue | $3.26B |
| Gross Profit | $4.07B |
| R&D Expenses | $564.00M |
| SG&A Expenses | $2.28B |
| Operating Expenses | $6.66B |
| Operating Income | $672.00M |
| Interest Expense | $134.00M |
| Net Income | $537.00M |
| EPS (Basic) | $0.30 |
| EPS (Diluted) | $0.30 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.79B |
Key Highlights
- 1Total net sales for Q2 2020 decreased by 8.2% to $7.33 billion, impacted by COVID-19, with Medical Devices sales down 21.2% and Diagnostic Products sales up 4.7%.
- 2Abbott launched six new COVID-19 diagnostic tests, generating $652 million in sales for the first six months of 2020, predominantly in the second quarter.
- 3Diabetes Care, driven by the FreeStyle Libre system, showed strong growth, with sales up 29.0% excluding foreign exchange for the first six months of 2020.
- 4Gross profit margin declined to 47.9% in Q2 2020 from 52.8% in Q2 2019, attributed to product mix, the pandemic's impact on certain segments, and increased amortization.
- 5The company issued $1.3 billion in senior notes to refinance existing debt, strengthening its liquidity position, with cash and equivalents increasing to $4.76 billion.
- 6Research and Development (R&D) expenses decreased 8.6% for the first six months of 2020, partly due to a significant R&D asset expensing in the prior year's comparable period.
- 7The company's legal proceedings accrual was $105 million, and management believes the ultimate disposition will not have a material adverse effect on the financial position.